Genomic and Proteomic Biomarkers for Head and Neck Cancer Risk and Prognosis

头颈癌风险和预后的基因组和蛋白质组生物标志物

基本信息

批准号：
7739901
负责人：
ANN MARIE EGLOFF
金额：
$ 10.09万
依托单位：
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
依托单位国家：
美国
项目类别：
财政年份：
2009
资助国家：
美国
起止时间：
2009-09-04 至 2014-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7739901
关键词：
Address Affect Age Archives Biological Markers Bombesin Receptor Cancer Patient Cancerous Case-Control Studies Characteristics Clinical DNA Data Data Collection Development Development Plans Disease Disease Progression Doctor of Philosophy Environmental Exposure Epidemiologist Epidermal Growth Factor Receptor Ethnic Origin Etiology Frequencies G-Protein-Coupled Receptors Gender Genetic Genetic Polymorphism Genetic Transcription Genomics Genotype Goals Haplotypes Head Cancer Head and Neck Cancer Head and Neck Squamous Cell Carcinoma Histologic Individual Instruction Logistic Regressions Malignant Neoplasms Mentors Messenger RNA Modeling Molecular Monitor Mucous Membrane Otolaryngology Pathologic Patients Phosphoproteins Populations at Risk Proteins Proteomics Receptor Gene Receptor Signaling Reporting Research Design Research Personnel Resources Risk Risk Factors Signal Transduction Pathway Smoking Specimen Technology Testing Tobacco Tobacco use Training Translational Research Tumor Tissue Universities Update Variant age effect alcohol exposure cancer epidemiology cancer risk career development case control conventional therapy design disorder control experience follow-up genetic variant improved insight malignant mouth neoplasm outcome forecast overexpression peripheral blood professor prognostic prognostic indicator programs receptor expression response sample collection sex tumor

项目摘要

DESCRIPTION (provided by applicant): Defining head and neck squamous cell carcinoma (HNSCC) prognostic and predictive biomarkers is anticipated to provide insights Into molecular contributors to disease progression and to contribute to HNSCC disease control. An ongoing effort by the Head and Cancer Program at the University of Pittsburgh has collected peripheral blood DNA from HNSCC cases and controls and demographic and tobacco use data beginning In 2000; tumor tissues have also been archived. Clinical, pathologic, and follow-up data continues to be collected for these 790 HNSCC cases. In addition to this large specimen and data collection, we have high-through-put genomic and proteomic technologies and expertise. We are therefore uniquely poised to evaluate biomarkers associated with HNSCC risk and prognosis. Epidermal growth factor receptor (EGFR) and gastrin-releasing peptide receptor (GRPR) are strongly implicated In HNSCC development/progression. Dr. Egloff proposes to: (1) determine whether EGFR/GRPR genetic variants are related to developing HNSCC using a case-control study; (2) determine whether EGFR/GRPR polymorphisms are prognostic indicators for HNSCC; and (3) evaluate correlations between HNSCC protein levels and EGFR/GRP R variant genotypes. These studies will be carried out with a carefully selected team of mentors and advisors who will provide expertise and guidance covering all aspects of the proposed studies. Dr. Egloff is an Assistant Professor in the Department of Otolaryngology, University of Pittsburgh with experience in translational research and formal training in cancer epidemiology and genetics. The candidate has outlined a career development plan including formal training in statistical genetics designed to facilitate her transition to an independent molecular epidemiologist cancer researcher. RELEVANCE (See instructions): The proposed studies will test the overall hypothesis that EGFR and GRPR genetic variants contribute to HNSCC risk and disease progression and are designed to gain insights into the molecular etiology of HNSCC and to define populations at risk for developing HNSCC and/or worse disease prognosis. Results of these studies are anticipated to inform treatment decisions and contribute significantly to HNSCC disease control.

描述（由申请人提供）：定义头颈部鳞状细胞癌（HNSCC）预后和预测性生物标志物有望为疾病进展的分子促进者提供见解，并为HNSCC疾病控制做出贡献。匹兹堡大学负责人和癌症计划的持续努力从2000年开始从HNSCC病例和对照组以及人口统计以及烟草使用数据中收集了外周血DNA。肿瘤组织也已存档。对于这790 HNSCC病例，继续收集临床，病理和随访数据。除了这个大型标本和数据收集外，我们还具有高通用的基因组和蛋白质组学技术和专业知识。因此，我们有独特的准备评估与HNSCC风险和预后相关的生物标志物。表皮生长因子受体（EGFR）和胃蛋白释放肽受体（GRPR）与HNSCC的发育/进展有很强的影响。 Egloff博士建议：（1）确定使用病例对照研究的EGFR/GRPR遗传变异与开发HNSCC有关；（2）确定EGFR/GRPR多态性是否是HNSCC的预后指标；（3）评估HNSCC蛋白水平与EGFR/GRP R变体基因型之间的相关性。这些研究将与精心挑选的导师和顾问团队一起进行，他们将提供涵盖拟议研究的各个方面的专业知识和指导。埃格洛夫（Egloff）博士是匹兹堡大学耳鼻喉科学系的助理教授，在癌症流行病学和遗传学方面的转化研究和正规培训方面经验。候选人概述了一项职业发展计划，包括旨在促进她向独立分子流行病学家癌症研究员过渡的统计遗传学的正式培训。相关性（请参阅说明）：拟议的研究将检验总体假设，即EGFR和GRPR遗传变异有助于HNSCC风险和疾病进展，并旨在洞悉HNSCC的分子病因，并在患有HNSCC和/或较差疾病预后的风险中定义人群。预计这些研究的结果将为治疗决策提供信息，并为HNSCC疾病控制做出重大贡献。